Q3 EPS Estimates for ALX Oncology Boosted by HC Wainwright

ALX Oncology Holdings Inc. (NASDAQ:ALXO) – HC Wainwright upped their Q3 2026 earnings per share estimates for shares of ALX Oncology in a research report issued to clients and investors on Monday, August 10th. HC Wainwright analyst S. Ramakanth now forecasts that the company will post earnings per share of ($0.13) for the quarter, up from their previous estimate of ($0.14). The consensus estimate for ALX Oncology’s current full-year earnings is ($0.61) per share. HC Wainwright also issued estimates for ALX Oncology’s Q4 2026 earnings at ($0.13) EPS, FY2026 earnings at ($0.55) EPS, Q1 2027 earnings at ($0.13) EPS, Q4 2027 earnings at ($0.15) EPS, FY2027 earnings at ($0.57) EPS, FY2028 earnings at ($0.46) EPS, FY2029 earnings at ($0.51) EPS and FY2030 earnings at ($0.50) EPS.

Other analysts also recently issued reports about the company. Weiss Ratings downgraded ALX Oncology from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, August 5th. Wall Street Zen upgraded ALX Oncology from a “sell” rating to a “hold” rating in a research note on Saturday, May 9th. Five research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $4.60.

ALX Oncology Price Performance

Shares of NASDAQ:ALXO opened at $2.06 on Thursday. ALX Oncology has a one year low of $0.80 and a one year high of $2.66. The stock has a market capitalization of $284.86 million, a price-to-earnings ratio of -1.82 and a beta of 0.42. The company has a 50-day simple moving average of $1.94 and a 200-day simple moving average of $1.97. The company has a debt-to-equity ratio of 0.07, a quick ratio of 9.71 and a current ratio of 9.71.

ALX Oncology (NASDAQ:ALXO) last posted its earnings results on Thursday, August 6th. The company reported ($0.13) EPS for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.01.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the company. venBio Partners LLC purchased a new position in ALX Oncology during the second quarter worth about $26,671,201,000. Redmile Group LLC lifted its position in ALX Oncology by 143.9% in the first quarter. Redmile Group LLC now owns 7,964,188 shares of the company’s stock valued at $15,968,000 after purchasing an additional 4,699,470 shares during the period. BlackRock Inc. purchased a new stake in ALX Oncology in the 2nd quarter valued at approximately $15,317,000. Vivo Capital LLC purchased a new stake in ALX Oncology in the 1st quarter valued at approximately $6,385,000. Finally, 5AM Venture Management LLC acquired a new position in ALX Oncology during the 2nd quarter worth approximately $6,328,663,000. 97.97% of the stock is currently owned by institutional investors and hedge funds.

ALX Oncology Company Profile

ALX Oncology, Inc is a clinical-stage biopharmaceutical company headquartered in Redwood City, California, focused on developing next-generation immuno-oncology therapies. The company’s mission is to harness and amplify both innate and adaptive immune responses to improve outcomes for patients with a range of solid tumors and hematologic malignancies.

The lead candidate in ALX Oncology’s pipeline is evorpacept (ALX148), a high-affinity CD47-blocking Fc-silenced fusion protein designed to enhance macrophage-mediated phagocytosis of cancer cells when combined with standard therapeutic antibodies or immune checkpoint inhibitors.